, (GLOBE NEWSWIRE) — (NASDAQ: ), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that Chairman and CEO , PharmD, will participate in a live Benzinga All Access event on , at . The appearance had previously been scheduled for , at .
The discussion will address the current unmet needs in Attention Deficit/Hyperactivity Disorder (ADHD), as well as the expansion of Cingulate’s PTR platform into the anxiety therapeutic area. will also provide a company overview.
The event may be viewed live on Benzinga’s YouTube channel, Benzinga All Access, and will also be available for viewing on Cingulate’s website at cingulate.com/investors.
About ®
(NASDAQ: ), is a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. With an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD), is identifying and evaluating additional therapeutic areas where PTR technology may be employed to develop future product candidates, including to treat anxiety disorders.
is headquartered in . For more information visit Cingulate.com
Investor Relations
Thomas Dalton
Vice President, Investor & Public Relations,
TDalton@cingulate.com
913-942-2301
mkreps@darrowir.com
214-597-8200
Media RelationsElixir Health Public Relations
mweible@elixirhealthpr.com
201-723-5805
Source:
2022 GlobeNewswire, Inc., source
Read More: Cingulate Benzinga All Live Access Appearance Rescheduled for December 16